GLP-1 Therapies Newsletter
Issue #14December 8, 20257 studies

GLP-1 drugs tied to 18% lower atrial fibrillation risk — and 7.8 point drop in alcohol use disorder scores

GLP-1 receptor agonists like Ozempic and Mounjaro are having a moment—but new research suggests their benefits extend far beyond weight loss and diabetes control.

🫀 GLP-1 drugs reduce heart rhythm problems in overweight people

  • 24 randomized trials with 40,694 participants found GLP-1 receptor agonists reduced atrial fibrillation risk by 18% compared to placebo

  • The heart protection appeared independent of how much weight people lost—suggesting the drugs have direct cardiac benefits

  • No differences were seen between single drugs (like semaglutide) versus newer combination drugs (like tirzepatide), or between oral versus injectable versions

Why it matters: Atrial fibrillation affects over 33 million people worldwide and dramatically increases stroke risk. These findings suggest GLP-1 drugs may protect the heart through mechanisms beyond just weight loss.

🥈 Top 2% journal 🔗 Metabolism: clinical and experimental Systematic Review 🗓️ Dec 5

Key Findings

🧠 Semaglutide helps schizophrenia patients avoid pre-diabetes

  • 73 people with schizophrenia taking antipsychotic drugs received weekly semaglutide or placebo for 26 weeks

  • Semaglutide reduced hemoglobin A1c by 0.25% and body weight by 9.2 kg compared to placebo

  • 43% of semaglutide users achieved low-risk blood sugar levels (<5.4%) versus just 3% with placebo

💡 May offer a way to prevent diabetes in people with schizophrenia, who face high metabolic risks from necessary psychiatric medications.
🥇 Top 1% journal 🔗 JAMA psychiatry Journal Article 🗓️ Dec 3

🍺 GLP-1 drugs linked to reduced alcohol problems

  • Meta-analysis of 14 studies covering over 5 million people found GLP-1 drugs reduced alcohol use disorder scores by 7.8 points on a 40-point scale

  • Large population studies showed lower risks of alcohol-related hospitalizations and diagnoses

  • Brain imaging studies revealed reduced alcohol cue reactivity and changes in reward pathways

💡 Could point to new treatment options for alcohol use disorder, especially in people who also have diabetes or obesity.
🥈 Top 2% journal 🔗 EClinicalMedicine Journal Article 🗓️ Dec 1

⚖️ Bariatric surgery still beats GLP-1 drugs for weight loss

  • Network analysis of 30 trials with 20,015 participants compared metabolic surgery to GLP-1 medications

  • Surgery achieved 10.3% greater total weight loss at 2+ years, plus bigger improvements in blood pressure and cholesterol

  • However, tirzepatide alone showed no significant difference from surgery in head-to-head comparisons

💡 Surgery remains the gold standard for severe obesity, but newer GLP-1 drugs like tirzepatide are closing the gap.
🎖️ Top 10% journal 🔗 Obesity (Silver Spring, Md.) Review 🗓️ Dec 1

🩺 WHO issues first global guidelines for GLP-1 obesity treatment

  • World Health Organization recommends long-term GLP-1 therapy combined with behavioral interventions for adults with obesity

  • Guidelines emphasize obesity as a chronic disease requiring lifelong care, not a lifestyle choice

  • Implementation depends on ensuring equitable access and preventing discrimination in healthcare settings

💡 Signals a major shift toward recognizing obesity as a medical condition deserving comprehensive, non-judgmental treatment.
🥇 Top 1% journal 🔗 JAMA Journal Article 🗓️ Dec 1

💰 Medicare patients face equity gaps in GLP-1 access

  • Among 13.9 million Medicare beneficiaries with type 2 diabetes, only 4.8% started semaglutide or tirzepatide in 2023

  • Black patients were 28% less likely to receive these drugs compared to white patients

  • Patients with dual Medicare-Medicaid coverage and those in socially vulnerable neighborhoods also had reduced access

💡 Highlights how social and economic barriers may prevent equitable access to breakthrough obesity and diabetes treatments.
🥇 Top 1% journal 🔗 Diabetes care Journal Article 🗓️ Dec 5

🔬 New AI system designs better triple-action diabetes drugs

  • Machine learning model analyzed 234 peptide sequences to optimize drugs targeting three hormone receptors simultaneously

  • Graph attention networks outperformed traditional methods, achieving 91.5% accuracy for glucagon receptor predictions

  • Genetic algorithm generated 20 promising new drug candidates with improved binding across all three targets

💡 Could accelerate development of more effective diabetes medications by using AI to design better multi-target drugs.
Top 20% journal 🔗 Frontiers in Bioinformatics Journal Article 🗓️ Dec 3

Implications

GLP-1 drugs are proving to be remarkably versatile medicines with benefits extending far beyond their original diabetes and weight-loss applications. However, ensuring equitable access and understanding their full range of effects—both beneficial and potentially harmful—remains a critical challenge as their use expands globally.

Studies in this issue

Primary sources used for this newsletter.

  1. Risk of irregular heartbeat with GLP-1 drugs in overweight or obese people: review of clinical trials
    main storyMetabolism: clinical and experimental2025-12-05PMID 41349790
  2. How drugs that activate GLP-1 receptors may affect alcohol drinking
    key findingEClinicalMedicine2025-12-01PMID 41324012
  3. Semaglutide and Early Metabolism Problems in People with Schizophrenia Spectrum Disorders: A Randomized Trial
    key findingJAMA psychiatry2025-12-03PMID 41335431
  4. World Health Organization Guidelines for Using GLP-1 Treatments to Manage Obesity in Adults
    key findingJAMA2025-12-01PMID 41324410
  5. Comparing Weight-Loss Surgery and GLP-1 Drugs for Effectiveness Using Combined Trial Data
    key findingObesity (Silver Spring, Md.)2025-12-01PMID 41326176
  6. Using machine learning to improve three-part peptide treatments for metabolic disease
    key findingFrontiers in bioinformatics2025-12-03PMID 41333850
  7. Understanding Why Some Medicare Patients Start Using New Diabetes Medications
    key findingDiabetes care2025-12-05PMID 41348220

Continue reading

All GLP-1 Therapies issues